HERTI 150MG INJ VIAL

About

HERTI 150MG INJ VIAL contains Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. This binding inhibits the proliferation of human tumor cells that overexpress HER2. It is a targeted therapy used in the treatment of certain cancers where HER2 overexpression is a key driver of disease progression.

Trastuzumab works by blocking the growth signals that HER2 sends to cancer cells, leading to reduced tumor growth and increased immune system activity against the cancer. Its mechanism of action makes it particularly effective in HER2-positive breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma, significantly improving patient outcomes when used alone or in combination with chemotherapy.

Uses

• Treatment of HER2-positive early breast cancer.
• Treatment of HER2-positive metastatic breast cancer.
• Treatment of HER2-positive metastatic gastric cancer.
• Adjuvant therapy after surgery, chemotherapy, and radiation for certain breast cancers.

Directions For Use

This medication is administered intravenously by a healthcare professional. The dosage and frequency are determined by your physician based on your condition.

Benefits

• Targets specific HER2-positive cancer cells.
• Improves progression-free survival in HER2-positive cancers.
• Enhances overall survival in eligible patients.
• Can be used in combination with chemotherapy for synergistic effects.
• Reduces the risk of cancer recurrence in early-stage disease.
• Offers a personalized treatment approach for HER2-driven tumors.

Side Effects

• Fever and chills
• Nausea and vomiting
• Diarrhea
• Headache
• Insomnia
• Rash
• Fatigue
• Anemia
• Neutropenia
• Cardiotoxicity (e.g., heart failure)
• Infusion-related reactions
• Peripheral neuropathy

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake during cancer treatment.
• Pregnancy - Trastuzumab can cause fetal harm. It is not recommended during pregnancy, and effective contraception should be used during treatment and for 7 months after the last dose.
• Breastfeeding - It is unknown if Trastuzumab is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for 7 months after the last dose.
• Liver - Use with caution in patients with pre-existing liver conditions. Liver function should be monitored regularly during treatment.
• Kidney - No specific dose adjustment is typically required for mild to moderate renal impairment, but caution is advised. Renal function should be monitored.
• Lung - Rare but serious pulmonary toxicity, including interstitial pneumonitis, has been reported. Patients should be monitored for new or worsening pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.